Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
33rd NZW-Hamburg33rd NZW-Hamburg
Not Confirmed
Not Confirmed
07-09 February, 2025
RNA TherapeuticsRNA Therapeutics
Not Confirmed
Not Confirmed
10-11 February, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
33rd NZW-Hamburg33rd NZW-Hamburg
Industry Trade Show
Not Confirmed
07-09 February, 2025
RNA TherapeuticsRNA Therapeutics
Industry Trade Show
Not Confirmed
10-11 February, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
09 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/grunenthal-appoints-prof-dr-uli-brodl-as-chief-scientific-officer-302346901.html
27 Nov 2024
// PHARMAWEB
https://www.pharmiweb.com/press-release/2024-11-27/gruenenthal-announces-pricing-of-500-million-bond#google_vignette
07 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with-qutenza-in-post-surgical-neuropathic-pain-302298768.html
22 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/first-participants-enrolled-in-first-in-human-phase-i-clinical-trial-with-nociceptin-nop-receptor-agonist-302283049.html
30 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer-302262571.html
23 Jul 2024
// Kevin Dunleavy FIERCE PHARMA
https://www.fiercepharma.com/pharma/grunenthal-continues-its-us-growth-push-250m-acquisition-valinor-pharma
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23754
Submission : 2010-04-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3156
Submission : 1978-03-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9811
Submission : 1992-08-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17166
Submission : 2004-02-18
Status : Active
Type : II